SHERIDAN, WYOMING – April 14, 2026 – Movano Health, the Pleasanton, California-based company behind the Evie Ring smart ring designed for women's health, has completed an all-stock merger with Corvex, marking a pivotal moment for a wearable health brand built around non-invasive biometric monitoring and women-first design. The deal closes as Movano continues pressing forward with a patented radio-frequency chip platform it says could eventually enable cuffless blood pressure and glucose tracking through a ring worn on the finger. For everyday consumers, and particularly women, the combination signals a company consolidating its resources around two of the most underserved frontiers in wearable health technology.
A Structural Shift Through Merger
The closing of the Corvex-Movano all-stock merger brings the two companies together in a shares-based combination. No specific financial terms were disclosed in available company materials. Separately, Movano's board of directors initiated a formal process to maximize shareholder value, a move that reflects active governance as the company moves into its next phase of development. The company is headquartered at 6800 Koll Center Pkwy in Pleasanton, California. The all-stock structure indicates the transaction was completed through an exchange of shares rather than a cash deal, a common approach when health technology companies combine to pool capabilities and extend their development runway.
The Evie Ring and the Women's Health Gap
The Evie Ring is Movano's flagship consumer product — a smart ring built from the ground up around women's health needs. The broader wearable market has long been shaped by male-default assumptions in hardware design and health algorithms, and Movano has explicitly positioned itself as a corrective to that gap. To deepen the science behind the product, the company partnered with an industry-leading researcher to examine the current state of biometric health research as it relates to women, and has committed to continuing progress in what it describes as a critical area. The company has also made its research report on breaking barriers in women's health available for download, signaling a broader educational commitment alongside its product development work.
Patented RF Technology Drives the Pipeline
At the core of Movano's longer-term product roadmap is a patented radio frequency technology platform. The company says it has designed the smallest custom radio frequency-enabled chip ever built for non-invasive and cuffless blood pressure and glucose monitoring. Both measurements carry significant health relevance: blood pressure is a leading cardiovascular risk indicator, and glucose monitoring is central to diabetes management. Delivering accurate readings through a passive ring sensor — without cuffs or skin-penetrating hardware — would substantially lower the barrier to daily health monitoring for millions of people. Movano states this RF chip work is actively driving its future product development. In February 2025, the company commenced a clinical study using a new cuffless blood pressure device, beginning the formal validation process that health technology requires before any path to wider consumer availability.
Why It Matters
For everyday consumers, especially women, reliable non-invasive health monitoring remains genuinely difficult to access outside of clinical settings. Blood pressure cuffs are bulky and require active use; continuous glucose monitors typically require a sensor inserted under the skin. A ring-format wearable that could passively and accurately capture these signals would represent a meaningful shift in how people engage with their own health data day to day. The merger with Corvex gives Movano a potentially strengthened capital base to carry its clinical work forward, while the Evie Ring anchors the brand in a real consumer product already on the market. One financial headwind remains visible: Movano received a Nasdaq deficiency notice in May 2025 related to a delayed quarterly filing, a reminder that early-stage health tech companies face significant regulatory and financial pressures even as their underlying science continues to advance.